Amgen, Novartis biosimilars news
The U.S. District Court for the Northern District of California denied a motion from Amgen for a preliminary injunction seeking to delay the launch of biosimilar Zarxio filgrastim-sndz from Novartis’ Sandoz Inc. generics unit over price erosion concerns that would cause the market to “irreversibly be changed.” The judge said the likelihood of Amgen wrongfully suffering irreparable harm appears speculative and “does not merit injunctive relief.” The biosimilar of Amgen’s Neupogen filgrastim is the first approved biosimilar product in the U.S. Amgen filed the brief in the U.S. District Court for the Northern District of California. Earlier this year, Amgen filed an appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC) after the district court denied Amgen’s motion for a preliminary injunction seeking to prevent a Zarxio launch (see BioCentury, March 23; March 30 & April 6). ...